At JosephCareRX, we believe in empowering our patients with knowledge about their health and treatment options
Eli Lilly recently launched two Phase 3 clinical trials for brenipatide, a GLP-1/GIP agonist, in alcohol use disorder [1]
Nestin, an intermediate filament protein, is associated with neural progenitor cells and is typically expressed during early stages of central and peripheral nervous system development
GLP-1 activates KATP channels in coronary pericytes as the effector of brain-gut-heart signalling mediating cardioprotection
We feared this from the beginning, when we urged cavalier owners to not particpate in the EPIC Trial in our Blog entry, "Beware the pimobendan/Vetmedin 'EPIC clinical trial': There is no upside." Hopefully, between now and when the actual (presumably peer-reviewed) article on the EPIC Trial is published, responsible professionals will re-take control of this process back from the manufacturer and not suggest that death before reaching congestive heart failure is an acceptable end result of giving their dogs pimobendan
[7] Rodriguez PJ, Goodwin Cartwright BM, Gratzl S, et al
